| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/07/2006 | US7008936 Such as (1S-1R*,3R*(E),7R*,10S*,11R*,12R*,16S*))-7,11-dihydroxy-8,8,10,12,16 -pentamethyl-3-(1-methyl-2-(2-methy l-4-thiazolyl)ethenyl)-4-aza-17-oxabicyclo(14.1.0)heptadecane-5,9-dione combined with carboplatin |
| 03/07/2006 | US7008935 novel sunscreen agents such as Dipotassium Salt of 2-(4-acetamidobenzylidene)malonic Acid or Dipiperidinium Salt of 2-(4-aminobenzylidene)malonic Acid; absorbing within the region of UV-B radiation; cosmetics; photostability, water solubility |
| 03/07/2006 | US7008934 For minimizing promethazine hydrochloride interactions with plasma proteins; injectable solutions |
| 03/07/2006 | US7008933 Process for prophylaxis and therapy of thrombotic processes employing heparin having particular average molecular weights |
| 03/07/2006 | US7008932 Hyaluronic acid in soft gel form |
| 03/07/2006 | US7008931 uses of various molecules inhibiting heparanase such as sulfated polysaccharides |
| 03/07/2006 | US7008930 Alkoxylated alkyl polyglucoside compounds made with mild reagents to avoid discoloration and mal odor |
| 03/07/2006 | US7008929 Sapogenin-based treatment |
| 03/07/2006 | US7008922 Transplantation antigen that can lead to rejection of HLA-matched male organ and bone marrow grafts by female recipients, and may play a role in pregnancy and spermatogenesis. However, the origin and function of H-Y |
| 03/07/2006 | US7008920 comprising pharmacologically active substance, drug absorbefacient and taurine compound or polyamine; suppressing or preventing damage of the intestinal mucous membrane |
| 03/07/2006 | US7008779 novel gene and protein designated PHELIX; in normal individuals, expressed only in testis, but expressed at high levels in advanced and metastatic prostate cancer, and expressed at lower levels in testicular, bladder, ovarian cancers |
| 03/07/2006 | US7008765 polynucleotides that code for prostate specific antigen proteins or polypeptides; cells containing the recombinant nucleic acid molecules; hybridomas containing the antibodies; kits containing probes or antibodies; prevention of prostate cancer |
| 03/07/2006 | US7008666 Method of inhibiting overactivity of phagocytes or lymphocytes in an individual |
| 03/07/2006 | US7008661 Oil/fat composition |
| 03/07/2006 | US7008649 administering compositions of eugenol and forskolin; for treating and/or preventing soft tissue cancer in mammals |
| 03/07/2006 | US7008648 Solvent extraction, distillation biomass |
| 03/07/2006 | US7008645 Bisphosphonate compound |
| 03/07/2006 | US7008643 Delivery system for biological material |
| 03/07/2006 | US7008642 allow delivery of a therapeutic substance to a diseased region without significant loss from blood or other fuild flow; simultaneous treatment of multiple regions of a particular lumen or network of lumens |
| 03/07/2006 | US7008641 Osmotic capsule containing controlled release venlafaxine in the core in combination with an antipsychotic agent in a rapid release external coat; useful for the treatment of depression, anxiety or psychosis related disorders |
| 03/07/2006 | US7008640 Mixture of drug, aminoacrylate polymer and acid |
| 03/07/2006 | US7008637 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder |
| 03/07/2006 | US7008636 such as 5'-Octadecyloxy-[1,1';3',1'']terphenyl-2'-yloxy acetic acid for inhibiting Protien-Tyrosine Phosphatases(PTPases) from rat liver microsomes in vitro; for treatment of associated obesity, glucose intolerance, diabetes mellitus, hypertension |
| 03/07/2006 | US7008633 Injection of a biocompatible polymer, polysaccharide or polyamino acid, a cross-linker, and therapeutic agent into tumor; hydrogel formed in the tumor retains the therapeutic agent |
| 03/07/2006 | US7008631 Administering tetracycline antibiotics |
| 03/07/2006 | US7008630 Controlling cell differentiation, cell proliferation; antiinflammatory agents; skin disorders |
| 03/07/2006 | US7008627 dermocosmetic blends useful for improving and treating hyperreactive skin conditions, allergic-type reactions and/or intolerance; anti-radical, anti-inflammatory and anti-allergenic; immunomodulatory activity |
| 03/07/2006 | US7008626 For use in resecting epithelium |
| 03/07/2006 | US7008618 Water soluble monomers and polymers for protecting substrates from ultraviolet light |
| 03/07/2006 | US7008616 Ephedrine or fenfluramine; aluminum foil coated with a thin layer of drug is heated to form vapor; which condenses to form aerosol; rapid peak plasma concentration |
| 03/07/2006 | US7008615 Delivery of anti-migraine compounds through an inhalation route |
| 03/07/2006 | US7008613 technetium labelled complexes; for the treatment or diagnosis of pathologies caused by attack on human cartilage, arthritis |
| 03/07/2006 | US7008444 Method of controlling body temperature while reducing shivering |
| 03/07/2006 | CA2332983C Sitostanol formulation with emulsifier to reduce cholesterol absorption |
| 03/07/2006 | CA2271263C Use of cinnamic acid or at least one of its derivatives in a composition for skin exfoliation, and said composition |
| 03/07/2006 | CA2265795C Therapeutic agent with quantitative consumption marker and method of monitoring therapeutic agent consumption |
| 03/07/2006 | CA2245123C Use of rosaceae plant extract as a bradykinin antagonist |
| 03/02/2006 | WO2006024044A2 Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrostone |
| 03/02/2006 | WO2006024018A2 Compositions for treating nociceptive pain |
| 03/02/2006 | WO2006023931A2 Kinase inhibitors |
| 03/02/2006 | WO2006023891A2 Ligand-dependant activation of nur77 and uses thereof |
| 03/02/2006 | WO2006023881A2 T type calcium channel blockers and the treatment of diseases |
| 03/02/2006 | WO2006023865A1 Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases |
| 03/02/2006 | WO2006023852A2 Modulators of muscarinic receptors |
| 03/02/2006 | WO2006023843A2 Novel heterocycles |
| 03/02/2006 | WO2006023821A2 Ligands for aldoketoreductases |
| 03/02/2006 | WO2006023778A2 Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| 03/02/2006 | WO2006023757A2 Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents |
| 03/02/2006 | WO2006023750A2 Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 03/02/2006 | WO2006023714A2 Dithiocarbamate derivatives and their use for treating cancer |
| 03/02/2006 | WO2006023707A2 2-aminothiophenecarboxamides useful as cancer chemotherapeutic agents |
| 03/02/2006 | WO2006023703A2 Method for treating sleep related breathing disorders |
| 03/02/2006 | WO2006023702A2 Method for treating sleep related breathing disorders with setiptiline |
| 03/02/2006 | WO2006023693A2 Multi-functional biocompatible coatings for intravascular devices |
| 03/02/2006 | WO2006023659A2 Novel polymorphs of azabicyclohexane |
| 03/02/2006 | WO2006023651A2 Extended treatment of multiple sclerosis |
| 03/02/2006 | WO2006023639A1 Methods and compositions for oral delivery of fts |
| 03/02/2006 | WO2006023630A2 The use of n-aryl diazaspiracyclic compounds in the treatment of addiction |
| 03/02/2006 | WO2006023629A2 Treatment of pediatric multiple sclerosis |
| 03/02/2006 | WO2006023617A2 Cyclic amide & ester pyrazinoylguanidine sodium channel blockers |
| 03/02/2006 | WO2006023603A2 Pde5 inhibitor compositions and methods for treating cardiac indications |
| 03/02/2006 | WO2006023590A1 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE Iϵ |
| 03/02/2006 | WO2006023586A2 Guanylhydrazone compounds, compositions, methods of making and using |
| 03/02/2006 | WO2006023573A2 Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers |
| 03/02/2006 | WO2006023562A2 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase |
| 03/02/2006 | WO2006023497A2 Intranasal delivery of antipsychotic drugs |
| 03/02/2006 | WO2006023496A2 Vaginal cream compositions, kits thereof and methods of using thereof |
| 03/02/2006 | WO2006023467A1 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Iϵ |
| 03/02/2006 | WO2006023462A1 Histamine h3 receptor agents, preparation and therapeutic uses |
| 03/02/2006 | WO2006023460A2 COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| 03/02/2006 | WO2006023457A1 COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| 03/02/2006 | WO2006023454A1 Crystalline form of a biphenyl compound |
| 03/02/2006 | WO2006023445A2 Psorospermin and analogues |
| 03/02/2006 | WO2006023440A2 Mitotic kinesin inhibitors |
| 03/02/2006 | WO2006023410A2 Small molecules that replace or agonize p53 function |
| 03/02/2006 | WO2006023397A2 Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
| 03/02/2006 | WO2006023395A2 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-(substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors |
| 03/02/2006 | WO2006023381A1 Pyrimidinone compounds |
| 03/02/2006 | WO2006023377A2 Biomimetic of evodia rutaecarpa fruit extract for amelioration of inflammation |
| 03/02/2006 | WO2006023347A1 Paroxetine formulations |
| 03/02/2006 | WO2006023342A2 Synergistic conjugated linoleic acid (cla) and carnitine combination |
| 03/02/2006 | WO2006023295A2 Pharmaceutical compositions comprising effervescent agents and fenofibrate |
| 03/02/2006 | WO2006023272A1 2-polycyclic propynyl adenosine analogs having a2a agonist activity |
| 03/02/2006 | WO2006023242A1 Benzoxazepine derivatives as selective estrogen receptor modulators |
| 03/02/2006 | WO2006023194A2 Improved photosensitizer formulations and their use |
| 03/02/2006 | WO2006023187A2 Cycloalkylamine derivatives as nk-1 /ssri antagonists |
| 03/02/2006 | WO2006023158A2 Mineralocorticoid receptor modulator compounds and methods, and pharmaceutical compositions containing these compounds |
| 03/02/2006 | WO2006022974A1 2-heteroarylalkenylcyclopentane heptan - (ene) - oic acid derivatives as therapeutc agents |
| 03/02/2006 | WO2006022966A1 2-heteroarylalkenylcyclopentane heptan- (ene) -oic acid derivatives as therapeutic agents |
| 03/02/2006 | WO2006022964A1 Tazarotenic acid and esters thereof for treating autism |
| 03/02/2006 | WO2006022955A2 Topoisomerase inhibitors |
| 03/02/2006 | WO2006022954A2 Benzoureas having anti-diabetic activity |
| 03/02/2006 | WO2006022773A1 Gyrase inhibitors and uses thereof |
| 03/02/2006 | WO2006022755A1 Risedronate compositions and their methods of use |
| 03/02/2006 | WO2006022611A2 Neuropathy cream |
| 03/02/2006 | WO2006022562A1 Improved chemical delivery formulations |
| 03/02/2006 | WO2006022544A1 Composition containing fermentable polysaccharides |
| 03/02/2006 | WO2006022543A1 Nutricional composition comprising immunoglobulins and oligosaccharides |
| 03/02/2006 | WO2006022542A1 Nutricional composition comprising indigestible oligosaccharides |
| 03/02/2006 | WO2006022450A1 Remedy for skin disease |